منابع مشابه
The ESA scenario gets complex: from biosimilar epoetins to activin traps.
Recombinant human erythropoietin (rhEpo, epoetin) has proved beneficial in preventing transfusion-dependent anaemia in patients with chronic kidney disease. Apart from copied epoetins distributed in less regulated markets, 'biosimilar' epoetins have gained currency in many regions, where they compete with the originals and with rhEpo analogues with prolonged survival in circulation ('biobetter'...
متن کاملBiosimilars Entry And Price Development In Europe.
In light of the increasing interest in pricing and entry of biosimilars in Europe, this research has found that the market of filgrastim biosimilars is dominated by the entry effect, while that of epoetins is driven by the competition effect. The epoetins market gets saturated relatively faster in terms of number of local competitors, which can be explained by the molecular complexity of that m...
متن کاملBiosimilar Therapeutic Monoclonal Antibodies
Last month, Part 1 of this discussion brief ly described the regulatory landscape for developing biosimilar therapeutic monoclonal antibodies (TMAbs). We identified certain specific structural components of TMAb drug substances that warrant particular attention because alterations to them are likely to affect therapeutic safety and effectiveness. Now we conclude by considering whether studies o...
متن کاملBiosimilar medicines and cost-effectiveness
Given that biosimilars are agents that are similar but not identical to the reference biopharmaceutical, this study aims to introduce and describe specific issues related to the economic evaluation of biosimilars by focusing on the relative costs, relative effectiveness, and cost-effectiveness of biosimilars. Economic evaluation assesses the cost-effectiveness of a medicine by comparing the cos...
متن کاملThe Future of Biosimilar Insulins
IN BRIEF Biosimilar insulins are available in many countries and will be made available in the United States in the near future. Some concerns associated with biosimilar insulins include potential differences in the efficacy and safety between a biosimilar product and its reference insulin, the ramifications of having the same name or different names for a biosimilar and its reference insulin, ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nephrology Dialysis Transplantation
سال: 2009
ISSN: 0931-0509,1460-2385
DOI: 10.1093/ndt/gfp111